Related Experiment Video
Updated: May 31, 2026

In Vitro Disassembly of Influenza A Virus Capsids by Gradient Centrifugation
Published on: March 27, 2016
Mechanism of 150-cavity formation in influenza neuraminidase
Rommie E Amaro1, Robert V Swift, Lane Votapka
1Department of Pharmaceutical Sciences, Computer Science and Chemistry, University of California, Irvine, California 92697, USA. ramaro@uci.edu
Abstract:
The recently discovered 150-cavity in the active site of group-1 influenza A neuraminidase (NA) proteins provides a target for rational structure-based drug development to counter the increasing frequency of antiviral resistance in influenza. Surprisingly, the 2009 H1N1 pandemic virus (09N1) neuraminidase was crystalized without the 150-cavity characteristic of group-1 NAs. Here we demonstrate, through a total sum of 1.6 μs of biophysical simulations, that 09N1 NA exists in solution preferentially with an open 150-cavity. Comparison with simulations using avian N1, human N2 and 09N1 with a I149V mutation and an extensive bioinformatics analysis suggests that the conservation of a key salt bridge is crucial in the stabilization of the 150-cavity across both subtypes. This result provides an atomic-level structural understanding of the recent finding that antiviral compounds designed to take advantage of contacts in the 150-cavity can inactivate both 2009 H1N1 pandemic and avian H5N1 viruses.
Insights
Influenza neuraminidase (NA) drug targets are key to combating antiviral resistance. Biophysical simulations reveal the 2009 H1N1 NA preferentially exists with an open 150-cavity, crucial for drug development.
Area of Science:
- Virology
- Structural Biology
- Drug Discovery
Background:
- Influenza A neuraminidase (NA) is a target for antiviral drugs.
- Antiviral resistance is an increasing problem in influenza treatment.
- The 150-cavity in group-1 NA proteins is a potential drug target.
Purpose of the Study:
- To investigate the solution structure of 2009 H1N1 pandemic virus neuraminidase (09N1 NA).
- To understand the structural basis for the presence or absence of the 150-cavity in 09N1 NA.
- To identify factors stabilizing the 150-cavity for drug design.
Main Methods:
- Biophysical simulations (1.6 μs total).
- Comparative simulations with avian N1, human N2, and a mutated 09N1.
- Bioinformatics analysis.
Main Results:
- 09N1 NA exists preferentially with an open 150-cavity in solution.
- A conserved salt bridge is crucial for stabilizing the 150-cavity.
- This stabilization is observed across different NA subtypes.
Conclusions:
- The 150-cavity is present in solution for 09N1 NA, contrary to crystal structures.
- Structural understanding of the 150-cavity aids in developing antivirals against resistant strains.
- Antiviral compounds targeting the 150-cavity can inactivate both pandemic H1N1 and avian H5N1 viruses.
More Related Videos
22:10Multi-target Parallel Processing Approach for Gene-to-structure Determination of the Influenza Polymerase PB2 Subunit
Published on: June 28, 2013
08:19Subnanometer-Resolution Structural Determination of Hemagglutinin from Cryo-Electron Tomography of Influenza Viruses
Published on: November 7, 2025
Related Concept Videos
Inhibitors Of Virion Release
Influenza
Leaky Scanning
Pinching-off of Coated Vesicles
SN2 Reaction: Mechanism
The presence of the more electronegative halogen in the substrate creates a polarized carbon-halide bond. The halide pulls the electron cloud generating an electrophilic center at the carbon atom. Thus, the carbon atom carries a partial positive charge while the halide has a...